Table 3.
Adverse events in ESRD and non-ESRD group.
| Adverse events | ESRD (%) | Non-ESRD (%) | p value |
|---|---|---|---|
| Any grade | 11 (100) | 84 (71.2) | 0.04 |
| Grade 3/4 | 7 (63.6) | 42 (35.6) | 0.07 |
| Neutropenia | 6 (54.5) | 27 (22.9) | 0.02 |
| Grade 3/4 | 4 (36.4) | 10 (8.5) | 0.004 |
| Anemia | 11 (100) | 54 (45.8) | 0.001 |
| Grade 3/4 | 6 (54.5) | 32 (27.1) | 0.07 |
| Thrombocytopenia | 8 (72.0) | 43 (36.4) | 0.02 |
| Grade 3/4 | 1 (9.1) | 16 (13.6) | 0.68 |
| Hepatitis | 3 (27.3) | 34 (28.8) | 0.91 |
| Fatigue | 2 (18.2) | ||
| Anorexia | 3 (27.3) | ||
| Skin* | 2 (18.2) | ||
| AE of specific interest | |||
| Ascites | 2 (18.2) | ||
| TB reactivation | 1 (9.1) | ||
| TENS | 1 (9.1) | ||
| CRS-like syndrome | 1 (9.1) |
AE, adverse event; TB, tuberculosis; TENS, toxic epidermal necrolysis; CRS, cytokine release syndrome; ESRD, end-stage renal disease.
*One TENS classified as grade 4 dermatologic toxicity.